- Open Access
Diagnosis of secondary amyloidosis in alkaptonuria
Diagnostic Pathology volume 9, Article number: 185 (2014)
Alkaptonuria (AKU) is an inborn error of catabolism due to a deficient activity of homogentisate 1,2-dioxygenase. Patients suffer from a severe arthropathy, cardiovascular and kidney disease but other organs are affected, too. We found secondary amyloidosis as a life-threatening complication in AKU, thus opening new perspectives for its treatment. We proved that methotrexate and anti-oxidants have an excellent efficacy to inhibit the production of amyloid in AKU model chondrocytes. Owing to the progressive and intractable condition, it seems important to detect amyloid deposits at an early phase in AKU and the choice of specimens for a correct diagnosis is crucial.
Ten AKU subjects were examined for amyloidosis; abdominal fat pad aspirates, labial salivary gland, cartilage and synovia specimens were analysed by CR, Th-T, IF, TEM.
Amyloid was detected in only one abdominal fat pad specimen. However, all subjects demonstrated amyloid deposition in salivary glands and in other organ biopsies, indicating salivary gland as the ideal specimen for early amyloid detection in AKU.
This is, at the best of our knowledge, the first report providing correct indications on the diagnosis of amyloidosis in AKU, thus offering the possibility of treatment of such co-morbidity to AKU patients.
The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/13000_2014_185
Amyloidosis is the deposition of insoluble protein aggregates either systemically or in a specific organ. Secondary (AA) amyloidosis is caused by a chronic infection or chronic inflammatory disease where deposits are made up of serum amyloid A (SAA) produced during inflammation.
We found SAA amyloidosis as a life-threatening complication in alkaptonuria (AKU) , an ultra-rare (1:250.000-1.000.000 incidence) autosomal recessive genetic disease due to a deficient activity of homogentisate 1,2-dioxygenase (HGD) leading to the accumulation of homogentisic acid (HGA). HGA-oxidized derivative benzoquinone acetic acid (BQA) forms deposits in the connective tissue, causing a pigmentation known as "ochronosis", leading to dramatic organ damage. A severe form of arthropathy is the most common clinical presentation of AKU, but all the organs can be affected, too. AKU can be treated symptomatically during the early stages, whereas for end stages total joint and heart valve replacements may be required. Currently, there is no therapy for AKU, although a clinical trial with nitisinone is in progress.
AA amyloidosis is one of the most severe complications of several chronic rheumatic disorders , and is a secondary complication of AKU due to a chronic inflammatory status derived from HGA/BQA-induced oxidative stress -. SAA-amyloid in AKU co-localizes with ochronotic pigment , AKU is a complicated inflammatory multisystemic disease, and any body district expressing HGD may be affected .
Our findings on AKU as a novel AA amyloidosis opened new perspectives for its treatment. In fact, the suppression of SAA below 10 mg/L halts the progression of the disease and is associated with prolonged survival, reversal of amyloid deposition and recovery of organ function . Methotrexate  and anti-oxidants  proved to have an excellent efficacy to inhibit the production of amyloid in AKU model chondrocytes, suggesting their introduction in AKU therapy.
Owing to AKU progressive and intractable condition, it is crucial to detect amyloid deposits at an early phase. As ascertained in other secondary amyloidosis, if SAA deposition cannot be stopped or delayed, serious life-threatening problems can arise . Therefore, SAA amyloidosis should be diagnosed as early as possible and the clinicians treating AKU patients need an easy routine reproducible fast procedure that can be repeated at intervals.
In this work, ten AKU subjects were examined for amyloidosis in abdominal fat pad aspirates and labial salivary gland (LSG) biopsies. Amyloid was detected in only one abdominal fat pad specimen. However, all subjects demonstrated amyloid deposition in LSGs and in other organ biopsies. These results further support the concept that LSG may be the optimal specimen for early detection of amyloid in AKU and that LSG offers improved sensitivity in respect to fat pad aspirates in these patients.
This is, at the best of our knowledge, the first report providing correct indications on the diagnosis of amyloidosis in AKU, thus offering the possibility of treatment of such co-morbidity to AKU patients.
Procedures were approved by Siena University Hospital and national Ethics (Comitato Etico Policlinico Universitario di Siena, number GGP10058, date 21/07/2010) in accordance with 1975 Helsinki Declaration, revised in 2000 (52nd WMA General Assembly, Edinburgh, Scotland, October 2000). Informed consent was obtained from all patients.
All reagents were from Sigma-Aldrich (St. Louis, MO), if not differently specified.
After reviewing AKU patients' medical history and laboratory values (Table 1 and 2), a clinical examination was completed and each subject underwent two biopsies of clinically normal-appearing tissue in the oral cavity under local anesthesia (2% lidocaine with 1:100,000 epinephrine). Specimen 1 was taken from the left lateral surface of the tongue, containing mucosal and muscle tissue. Specimen 2 was taken from the labial mucosa on the left side of the lower lip, containing at least 2 to 3 minor salivary glands. Both specimens were formalin fixed and analyzed for histopathologic evaluation of amyloid.
Patients underwent a subcutaneous abdominal fat biopsy via fine-needle aspiration. Skin and subcutaneous tissue around the umbilicus of the patients were anesthetized with 1% lidocaine. The fat was aspirated with an 18-gauge needle connected to a 20 ml syringe. At least two visible fragments of fat were placed on a glass slide and crushed into a single layer by pressing a second slide against the first. After the smears were dried in air at 50°C for at least 30 minutes and fixed with 20% formalin neutral buffer solution (Wako Pure Chemical, Osaka, Japan) for 5 minutes, these specimens were processed for the Congo Red staining.
Cartilage and synovia
Articular cartilage fragments, from AKU subjects who underwent surgery for joint replacement, were placed in 5% formaldehyde. Samples were alcohol dehydrated and paraffin embedded.
Valve was obtained from an AKU subject who underwent biologic aortic valve replacement.
The stone was from the prostate gland of an AKU subject who underwent surgical exploration for calculus removal.
Hematoxylin and Eosin (H&E) staining
Two sections (5 μm thickness) were obtained from each biopsy. Sections were stained with traditional hematoxylin/eosin (H/E) staining.
Congo Red (CR) staining
Romhányi's CR staining method modified according to Bély and Apáthy (2000) was adopted. 5 μm sections of fresh specimen were fixed in cooled 96% ethanol 10 min, rinsed in water, incubated in 1% CR for 40 min, washed in water, incubated 10 s in 1 ml 1% sodium hydroxide in 100 ml of 50% ethanol, incubated 30 s in Mayer's hematoxylin, sequentially washed in 50%, 75%, 95% ethanol, mounted and observed under a polarized light microscope (Zeiss Axio Lab.A1, Arese, Milano).
Thioflavin T (Th-T) staining
AKU samples in paraffin were cut in 3-5 μm slices and double immunofluorescence stained with anti-SAA and anti-serum amyloid P (SAP) antibodies (Santa Cruz Biotechnology, CA). Nuclei were counter-stained with blue DAPI DNA stain (Abcam, Cambrige, UK).
Transmission electron microscopy (TEM)
AKU specimens were fixed in 2.5% glutaraldehyde in 0.1 M cacodylate buffer (CB) pH 7.2 for 3 h at 4°C, post-fixed in 1% osmium tetroxide in CB for 2 hours at 4°C, ethanol dehydrated and embedded in a mixture of Epon-Araldite resins. Thin sections, obtained with a Reichert ultramicrotome, were stained with uranyl acetate and lead citrate and observed with a TEM FeiTecnai G2 spirit at 80 Kv.
Structural features of AKU salivary glands were first evaluated by means of H&E staining (representative images are presented in Figure 1A-B). Parenchyma was found to be compact only in some limited areas; by contrast, a number of vacuoles and a disrupted acinar structure were present in the vast majority of the specimen. All of the AKU salivary glands that were examined did not contain any trace of lymphocytic infiltration.
In order to diagnose amyloidosis in AKU patients, diagnostic laboratories adopted periumbelical fat aspirate CR staining  that unfortunately proved to be unsuitable for the detection of amyloid deposits in AKU patients. Indeed, we studied abdominal fat pad aspirates and labial salivary gland biopsies from 10 AKU patients in whom subsequent other tissue biopsies for confirmation of AA amyloidosis were also available. All cases were suspected to have SAA deposits, but nine of them had negative results on abdominal fat pad aspirates evaluated by polarizing microscopy of CR stained sections (not shown). CR staining of fat aspirates from three different hospital laboratories were compared in all samples for studying inter observer reproducibility and gave negative diagnosis of amyloidosis in nine cases out of ten.
Once CR staining was adopted on AKU LSGs, the results were unequivocally positive for all ten patients (Figure 2A).
To confirm the presence of amyloid aggregates in LSG from AKU patients, we performed the Th-T assay. Th-T fluorescence was evident in all examined samples (10/10) (Figure 2B). Moreover, by means of immunofluorescence techniques, we assessed the presence of SAA deposition in LSG (Figure 3).
Ultrastructural analysis by TEM of AKU LSGs (the current `gold standard' for detecting amyloid deposits also in ambiguous cases), confirmed the massive presence of amyloid fibrils in all specimens. Amyloid deposits in LSG were abundant in six patients, moderate in three, and mild in one (Table 1). Figure 4 shows fine fibrils, approximately 10 nm in diameter, located in the secretory stroma of AKU salivary glands of patient #1, adjacent to the basement membrane. The fibrils were also present in the interstitial connective tissue, interspersed with collagen fibrils (Figure 4A) and around interlobular ducts of salivary glands of all patients. In all observed samples, the glandular stroma contained numerous broken collagen fibrils strictly interconnected with amyloid fibrils arranged in a scattered manner. Moreover, thanks to TEM analysis, it was possible to see evident pigment traces finely sprinkled over the whole tissue (Figure 4B-F). In particular, pigment deposits could be seen as individual "drop-like" deposits between the collagen fibers and also scattered over amyloid bundles of fibrils.
Our study showed, for the first time, that, analogously to other AKU tissues ,, also in LSG amyloid and pigment were strictly interconnected and that collagen fibrils seemed to feel the effect of destructive action of both pigment and amyloid, appearing constantly broken and damaged when sprinkled and invaded by these two elements. The presence of ochronotic pigmentation in less commonly examined areas of human body, such as glandular tissues, may provide insights into the mechanisms of pigment formation and deposition. Here, we presented evidence to support the probable association of HGA oxidised products with collagen and the existence of extracellular mechanisms, like as amyloid deposition, mediating ochronotic pigmentation that overlaps in tissues.
The tissue source impacts the likelihood of discovering amyloid deposits. Bone marrow biopsy sensitivity has been estimated at 63% . Kidney, liver, or cardiac biopsies have sensitivity as high as 87-98% but are more invasive . Rectal biopsy sensitivity ranges from 69% to 97% depending upon the quantity of tissue sampled. Tissue source also impacts amyloid typing. The chemical type of amyloid that deposits in AKU is amyloid A protein and since this type of amyloid involves diffusely the mucosa and the submucosa , it may be better to prefer location as the oral cavity or gastrointestinal tract to detect them. In particular, LSG biopsy is less invasive and cheaper than examination of rectal mucosa. In the last years, various studies have demonstrated the utility of LSG biopsy for the detection of amyloid with correlation to secondary systemic amyloidosis ,.
Amyloid deposition is a dynamic process that can progress and stabilize. Quantification of SAA concentration in tissue on regular occasions will similarly reflect the accumulation, stabilization or even regression of deposited amyloid. Abdominal subcutaneous fat tissue seems to be very suitable for this purpose ,, because it is easy to obtain by aspiration, but, at least in some cases, it has limited sensitivity and turned out inadequate -. In fact, subcutaneous abdominal fat CR staining is positive in approximately 80% of patients with AL amyloidosis and less than 65% of patients with AA amyloidosis . Thus, the negative result on staining of the abdominal-fat aspirate in AKU cases does not necessarily indicate negativity of amyloidosis at the diagnosis. Moreover, Tribe  did not recommend the use of subcutaneous fat aspiration because he reported that "fat is rarely involved". Libbey et al.  reported a 20% false negative result rate. It thus appears that abdominal fat aspiration is a method not enough sensitive to detect AA in rheumatic diseases.
In all ten AKU samples, amyloid deposits were identified so underlining the high sensitivity of LSG biopsy in the diagnosis of amyloidosis, even in the absence of other symptoms.
LSG biopsy appears as a simple and safe method to detect generalized amyloidosis in patients with a chronic inflammatory disease such as AKU. The results of our pilot study demonstrate that the prevalence of occult amyloid deposition in patients with AKU may be very high. Since a prompt detection of amyloid may have significant clinical and economic implications in AKU, it is fundamental to establish accurately the association of synchronous amyloidosis. In our limited size sample, due to ultra-rarity of the disease, the majority of AKU patients had no detectable amyloid deposition on fat pad aspirate. However, we were able to detect amyloid deposition in minor LSG in all AKU patients. This suggests that subclinical amyloid deposition may be more easily detected on oral biopsies, and the oral cavity may be the preferred biopsy site for detecting amyloid deposition in AKU patients with no symptoms of systemic amyloidosis.
Our study suggests that minor LSG, especially when the biopsy of affected are lacking, may be the gold standard for the diagnosis of SAA amyloidosis in AKU.
Labial salivary gland
Serum amyloid A
Serum amyloid P
Millucci L, Spreafico A, Tinti L, Braconi D, Ghezzi L, Paccagnini E, Bernardini G, Amato L, Laschi M, Selvi E, Galeazzi M, Mannoni A, Benucci M, Lupetti P, Chellini F, Orlandini M, Santucci A: Alkaptonuria is a novel human secondary amyloidogenic disease. Biochim Biophys Acta. 1822, 2012: 1682-1691.
Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, Hawkins PN: Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007, 356: 2361-2371. 10.1056/NEJMoa070265.
Obici L, Raimondi S, Lavatelli F, Bellotti V, Merlini G: Susceptibility to AA amyloidosis in rheumatic diseases: a critical overview. Arthritis Rheum. 2009, 61: 1435-1440. 10.1002/art.24735.
Bernardini G, Braconi D, Spreafico A, Santucci A: Post-genomics of bone metabolic dysfunctions and neoplasias. Proteomics. 2012, 12: 708-721. 10.1002/pmic.201100358.
Braconi D, Bernardini G, Bianchini C, Laschi M, Millucci L, Amato L, Tinti L, Serchi T, Chellini F, Spreafico A, Santucci A: Biochemical and proteomic characterization of alkaptonuric chondrocytes. J Cell Physiol. 2012, 227: 3333-3343. 10.1002/jcp.24033.
Braconi D, Bianchini C, Bernardini G, Laschi M, Millucci L, Spreafico A, Santucci A: Redox-proteomics of the effects of homogentisic acid in an in vitro human serum model of alkaptonuric ochronosis. J Inherit Metab Dis. 2011, 34: 1163-1176. 10.1007/s10545-011-9377-6.
Braconi D, Laschi M, Amato L, Bernardini G, Millucci L, Marcolongo R, Cavallo G, Spreafico A, Santucci A: Evaluation of anti-oxidant treatments in an in vitro model of alkaptonuric ochronosis. Rheumatology (Oxford). 2010, 49: 1975-1983. 10.1093/rheumatology/keq175.
Braconi D, Laschi M, Taylor AM, Bernardini G, Spreafico A, Tinti L, Gallagher JA, Santucci A: Proteomic and redox-proteomic evaluation of homogentisic acid and ascorbic acid effects on human articular chondrocytes. J Cell Biochem. 2010, 111: 922-932. 10.1002/jcb.22780.
Spreafico A, Millucci L, Ghezzi L, Geminiani M, Braconi D, Amato L, Chellini F, Frediani B, Moretti E, Collodel G, Bernardini G, Santucci A: Antioxidants inhibit SAA formation and pro-inflammatory cytokine release in a human cell model of alkaptonuria. Rheumatology (Oxford). 2013, 52: 1667-1673. 10.1093/rheumatology/ket185.
Tinti L, Spreafico A, Braconi D, Millucci L, Bernardini G, Chellini F, Cavallo G, Selvi E, Galeazzi M, Marcolongo R, Gallagher J, Santucci A: Evaluation of antioxidant drugs for the treatment of ochronotic alkaptonuria in an in vitro human cell model. J Cell Physiol. 2010, 225: 84-91. 10.1002/jcp.22199.
Tinti L, Spreafico A, Chellini F, Galeazzi M, Santucci A: A novel ex vivo organotypic culture model of alkaptonuria-ochronosis. Clin Exp Rheumatol. 2011, 29: 693-696.
Tinti L, Taylor AM, Santucci A, Wlodarski B, Wilson PJ, Jarvis JC, Fraser WD, Davidson JS, Ranganath LR, Gallagher JA: Development of an in vitro model to investigate joint ochronosis in alkaptonuria. Rheumatology (Oxford). 2011, 50: 271-277. 10.1093/rheumatology/keq246.
Laschi M, Tinti L, Braconi D, Millucci L, Ghezzi L, Amato L, Selvi E, Spreafico A, Bernardini G, Santucci A: Homogentisate 1,2 dioxygenase is expressed in human osteoarticular cells: implications in alkaptonuria. J Cell Physiol. 2012, 227: 3254-3257. 10.1002/jcp.24018.
Nakamura T: Clinical strategies for amyloid A amyloidosis secondary to rheumatoid arthritis. Mod Rheumatol. 2008, 18: 109-118. 10.3109/s10165-008-0035-2.
Picken MM, Herrera GA: Thioflavin T Stain: An Easier and More Sensitive Method for Amyloid Detection. Amyloid and Related Disorders. Current Clinical Pathology. Edited by: Picken MM, Dogan A, Herrera GA. 2012, Springer - Humana Press, Totowa, NJ, 187-189.
Saeed SM, Fine G: Thioflavin-T for amyloid detection. Am J Clin Pathol. 1967, 47: 588-593.
Libbey CA, Skinner M, Cohen AS: Use of abdominal fat tissue aspirate in the diagnosis of systemic amyloidosis. Arch Intern Med. 1983, 143: 1549-1552. 10.1001/archinte.1983.00350080055015.
van Gameren I, Hazenberg BP, Bijzet J, van Rijswijk MH: Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice. Arthritis Rheum. 2006, 54: 2015-2021. 10.1002/art.21902.
Blancas-Mejia LM, Ramirez-Alvarado M: Systemic amyloidoses. Annu Rev Biochem. 2013, 82: 745-774. 10.1146/annurev-biochem-072611-130030.
Hachulla E, Janin A, Flipo RM, Saile R, Facon T, Bataille D, Vanhille P, Hatron PY, Devulder B, Duquesnoy B: Labial salivary gland biopsy is a reliable test for the diagnosis of primary and secondary amyloidosis. A prospective clinical and immunohistologic study in 59 patients. Arthritis Rheum. 1993, 36: 691-697. 10.1002/art.1780360518.
Sacsaquispe SJ, Antunez-de Mayolo EA, Vicetti R, Delgado WA: Detection of AA-type amyloid protein in labial salivary glands. Med Oral Patol Oral Cir Bucal. 2011, 16: e149-e152. 10.4317/medoral.16.e149.
Masouye I: Diagnostic screening of systemic amyloidosis by abdominal fat aspiration: an analysis of 100 cases. Am J Dermatopathol. 1997, 19: 41-45. 10.1097/00000372-199702000-00008.
Ansari-Lari MA, Ali SZ: Fine-needle aspiration of abdominal fat pad for amyloid detection: a clinically useful test?. Diagn Cytopathol. 2004, 30: 178-181. 10.1002/dc.10370.
Buxbaum J: The Amyloidoses. Rheumatology. Edited by: Klippel JH Dieppe DA. , Mosby, London, 1-10. 2
Halloush RA, Lavrovskaya E, Mody DR, Lager D, Truong L: Diagnosis and typing of systemic amyloidosis: The role of abdominal fat pad fine needle aspiration biopsy. Cytojournal. 2010, 6: 24-
Tribe CR: Diagnosis of amyloidosis. Br Med J. 1976, 2: 943-10.1136/bmj.2.6041.943.
This work has been supported by Telethon Italy grant GGP10058.
The authors thank alkaptonuric patients who generously donated samples for the present study, AimAKU (Associazione Italiana Malati di Alcaptonuria, ORPHA263402), Toscana Life Sciences Orphan_1 project and Fondazione Monte dei Paschi di Siena 2008-2010, Drs. M. Benucci, A. Mannoni, E. Selvi. The authors also thank Dr. Elisa Vannuccini for TEM analysis.
The authors declare that they have no competing interests.
LM: conception and design of the study, acquisition of data, collection and assembly of data, analysis and interpretation of data, drafting the article, final approval of the version to be submitted. LG: acquisition of data, drafting the article, final approval of the version to be submitted. GB: acquisition of data, drafting the article, final approval of the version to be submitted. DB: acquisition of data, drafting the article, final approval of the version to be submitted. PL: acquisition of data, drafting the article, final approval of the version to be submitted. FP: provision of study materials, analysis and interpretation of data, revising critically for important intellectual content, final approval of the version to be submitted. MO: acquisition of data, drafting the article, final approval of the version to be submitted. AS: conception and design of the study, acquisition of data, analysis and interpretation of data, drafting the article, revising it critically for important intellectual content, obtaining of funding, final approval of the version to be submitted, responsible for the integrity of the work as a whole. All authors read and approved the final manuscript.
About this article
Cite this article
Millucci, L., Ghezzi, L., Bernardini, G. et al. Diagnosis of secondary amyloidosis in alkaptonuria. Diagn Pathol 9, 185 (2014). https://doi.org/10.1186/s13000-014-0185-9
- Serum amyloid A
- Secondary amyloidosis
- Salivary gland
- Periumbelical fat
- Congo Red